ReviewMaterials (Basel, Switzerland)2018
Phenotypic Variation during Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design.
Review in Materials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Proactive Strategies to Prevent Biofilm-Associated Infections: From Mechanistic Insights to Clinical Translation.Microorganisms · 2025Review
- Chemical Elements and Thickness of Candida albicans Biofilm Induced by Glucose, Lactose, Protein, and Iron.European journal of dentistry · 2025Article
- Pseudomonas aeruginosa clinical isolates in Egypt: phenotypic, genotypic, and antibiofilm assessment of Pluronic F-127.BMC microbiology · 2025Article
- Salicylic Acid-Mediated Silver Nanoparticle Green Synthesis: Characterization, Enhanced Antimicrobial, and Antibiofilm Efficacy.Pharmaceutics · 2025Article
- Article
- Microbial Biofilms: Features of Formation and Potential for Use in Bioelectrochemical Devices.Biosensors · 2024Review
- A review on mycogenic metallic nanoparticles and their potential role as antioxidant, antibiofilm and quorum quenching agents.Heliyon · 2024Review
- Understanding the intricacies of microbial biofilm formation and its endurance in chronic infections: a key to advancing biofilm-targeted therapeutic strategies.Archives of microbiology · 2024Review
- Comparative analysis of biofilm characterization of probioticFrontiers in microbiology · 2024Article
- Bayesian estimation ofBiofilm · 2023Article
- Review of the Impact of Biofilm Formation on RecurrentMicroorganisms · 2023Review
- Comprehensive Review on the Use of Biocides in Microbiologically Influenced Corrosion.Microorganisms · 2023Review
- Tobramycin Nanoantibiotics and Their Advantages: A Minireview.International journal of molecular sciences · 2022Review
- Multidrug-Resistant Biofilm, Quorum Sensing, Quorum Quenching, and Antibacterial Activities of Indole Derivatives as Potential Eradication Approaches.BioMed research international · 2022Review
- Article
- Nanotargeting of Resistant Infections with a Special Emphasis on the Biofilm Landscape.Bioconjugate chemistry · 2021Review
- Review
- Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System.Materials (Basel, Switzerland) · 2020Article
- Lactobacilli spp.: real-time evaluation of biofilm growth.BMC microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various bacterial species cycle between growth phases and biofilm formation, of which the latter facilitates persistence in inhospitable environments. These phases can be generally characterized by one or more cellular phenotype(s), each with distinct virulence factor functionality. In addition, a variety of phenotypes can often be observed within the phases themselves, which can be dependent on host conditions or the presence of nutrient and oxygen gradients within the biofilm itself (i.e., microenvironments). Currently, most anti-biofilm strategies have targeted a single phenotype; this approach has driven effective, yet incomplete, protection due to the lack of consideration of gene expression dynamics throughout the bacteria’s pathogenesis. As such, this article provides an overview of the distinct phenotypes found within each biofilm development phase and demonstrates the unique anti-biofilm solutions each phase offers. However, we conclude that a combinatorial approach must be taken to provide complete protection against biofilm forming bacterial and their resulting diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.